Initiation of PIMs associated with higher risk of fracture-specific hospitalizations and mortality

NewsGuard 100/100 Score

A recent study published in The European Journal of Health Economics finds that the initiation of potentially inappropriate medication (PIM) is associated with a higher risk of fracture-specific hospitalizations and mortality. Initiation of a PIM is also associated with higher hospital costs. The study was conducted on the basis of collaboration between the University of Eastern Finland, Fimea and The Social Insurance Institution of Finland.

PIMs are defined as medications whose potential risks are higher than their clinical benefits. In this study, PIMs were defined according to the Meds75+ database maintained by the Finnish Medicines Agency (Fimea). Medications are divided into four categories: A "Suitable for the older persons", B "There is little evidence, practical evidence or efficacy in older persons", C "Suitable for older persons, with specific cautions", and D "Avoid use in older persons". The most commonly used international criteria (Beers, STOPP/START and Laroche) were taken into account when creating the database.

Nationwide registers were used to follow over 20,000 community-dwelling people aged ≥65 years between the years 2002 and 2013. Matching persons were identified from the non-users group for those persons who purchased PIMs during the 12-year follow-up. The study indicates that the risk of fracture-specific hospitalization and mortality is higher when initiating PIMs. Previous studies conducted in Europe have not investigated hospital costs associated with PIM use with as long a follow-up as this study.

PIM prescription always requires clinical grounds, which take account of the risks related to medication treatments. The purpose of the Meds75+ database is to support clinical decision-making on the pharmacotherapy of patients over 75 years of age and to improve the safety of medication in primary health care. Meds75+ is available free of charge at Fimea's website.​

Source: https://www.uef.fi/en/-/iakkailla-valtettavien-laakkeiden-aloittaminen-lisaa-murtumien-ja-kuolleisuuden-riskia-seka-sairaalakustannuksia

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates